Serum biomarkers are molecules produced by normal and abnormal cells. Prostate specific
antigen (PSA) is an example of a serum biomarker used widely in the diagnosis and …

Prostate cancer (PCa) is the second most common cancer in men worldwide. A large
proportion of PCa are latent, never destined to progress or affect the patients' life. It is of …

Background The use of biomarkers for prostate cancer screening, diagnosis and prognosis
has the potential to improve the clinical management of the patients. Owing to inherent …

Simple Summary Prostate cancer is a leading cause of cancer-related death among males.
Many treatments are available to manage the disease, but despite this, ultimately advanced …

Prostate cancer is the second leading cause of cancer death in men and there is an urgent
clinical need to improve its detection and treatment. The introduction of prostate-specific …

Prostate cancer (PCa) is a leading cause of cancer-related death of men globally. Since its
introduction, there has been intense debate as to the effectiveness of the prostate specific …

Prostate‐specific antigen (PSA) is the main diagnostic tool when it comes to prostate cancer
but it possesses serious limitations. Therefore, there is an urgent need for more sensitive …

Prostate cancer (PCa), a highly heterogeneous disease, is the one of the leading cause of
morbidity and mortality in the developed countries. Historically used biomarkers such as …

The widespread use of the PSA test has led to increased detection of the disease at earlier
stages and a reduction in the number of patients where metastatic disease is found at …

Although prostate cancer (PCa) is the most commonly diagnosed cancer in men, most
patients do not die from the disease. Prostate specific antigen (PSA), the most widely used …